** Shares in Genmab GMAB.CO are up nearly 7% following positive EPKINLY combo trial data release

** J.P.Morgan highlights strong progression-free survival results from the study including epcoritamab, approved under the brand name EPKINLY, and lenalidomide

** The brokerage says the progression-free survival, a measure of time lived without the disease worsening, came ahead of its expectations, and aligns with Roche therapies

** Success in this trial is needed to convert the accelerated regulatory approval of the therapy into a full approval, it adds

** JPM notes, however, that overall patient survival data remains immature at this stage and detailed findings at an upcoming medical meeting are required to fully assess the commercial potential

** Genmab is the top gainer on the pan-European STOXX 600 index .STOXX

** The stock, at its highest since April, is on track for its best day since February 2025